Oncternal Therapeutics (NASDAQ:ONCT) PT Lowered to $28.00 at HC Wainwright

Oncternal Therapeutics (NASDAQ:ONCT) had its price target reduced by HC Wainwright from $30.00 to $28.00 in a research report report published on Monday, Benzinga reports. They currently have a buy rating on the stock.

Separately, StockNews.com raised shares of Oncternal Therapeutics from a sell rating to a hold rating in a report on Friday, March 8th.

Oncternal Therapeutics Price Performance

Shares of Oncternal Therapeutics stock opened at $8.71 on Monday. The firm has a market cap of $23.42 million, a P/E ratio of -0.64 and a beta of 1.26. The firm has a 50 day simple moving average of $8.92 and a 200 day simple moving average of $8.11. Oncternal Therapeutics has a fifty-two week low of $5.57 and a fifty-two week high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($3.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.09) by ($0.02). Oncternal Therapeutics had a negative net margin of 5,029.17% and a negative return on equity of 95.87%. The company had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.17 million. During the same period in the prior year, the business earned ($4.00) EPS. On average, sell-side analysts expect that Oncternal Therapeutics will post -12.03 EPS for the current year.

Insider Transactions at Oncternal Therapeutics

In other news, Director Robert James Wills purchased 6,914 shares of Oncternal Therapeutics stock in a transaction dated Thursday, March 28th. The shares were bought at an average cost of $8.48 per share, with a total value of $58,630.72. Following the completion of the transaction, the director now directly owns 6,914 shares in the company, valued at approximately $58,630.72. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have bought a total of 10,714 shares of company stock valued at $92,736 over the last three months. 8.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Oncternal Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Oncternal Therapeutics by 34.1% during the third quarter. Vanguard Group Inc. now owns 2,863,217 shares of the company’s stock worth $2,553,000 after purchasing an additional 728,200 shares in the last quarter. Millennium Management LLC lifted its position in Oncternal Therapeutics by 187.9% in the 2nd quarter. Millennium Management LLC now owns 1,296,115 shares of the company’s stock valued at $1,439,000 after acquiring an additional 845,991 shares in the last quarter. Renaissance Technologies LLC lifted its position in Oncternal Therapeutics by 52.2% in the 3rd quarter. Renaissance Technologies LLC now owns 979,800 shares of the company’s stock valued at $874,000 after acquiring an additional 336,066 shares in the last quarter. Pasadena Private Wealth LLC lifted its position in Oncternal Therapeutics by 79.4% in the 4th quarter. Pasadena Private Wealth LLC now owns 500,000 shares of the company’s stock valued at $268,000 after acquiring an additional 221,250 shares in the last quarter. Finally, Richmond Brothers Inc. lifted its position in Oncternal Therapeutics by 69.8% in the 3rd quarter. Richmond Brothers Inc. now owns 494,042 shares of the company’s stock valued at $148,000 after acquiring an additional 203,010 shares in the last quarter. 16.05% of the stock is owned by institutional investors.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.